Figure 4. Effects of Src inhibition with dasatinib on cell signaling.

Cells from BxPC3 (A), and PANC1 (B) were treated with DMSO or dasatinib (0-1000 nmol/L) for 12 h, lysed, and analyzed by Western blotting with indicated antibodies. Blots are representative of at least two separate experiments with similar results. There is a lack of inhibition of pSTAT3 and pMAPK signaling with dasatinib in PANC1 cells. (C) BxPC3 cells were treated with dasatinib (5 nmol/L) for 12 h. There was a significant decrease in expression of c-Myc and cyclin-D1 by immunofluorescence.